

|  |              |
|--|--------------|
| <b>Series foreword</b>   | <b>xi</b>    |
| <b>Foreword</b> Colin Walker                                     | <b>xv</b>    |
| <b>Preface</b>   | <b>xvii</b>  |
| <b>Acknowledgements</b>  | <b>xxiii</b> |
| <br>   |              |
| <b>1 Scope and limitations of classical hazard assessment</b>    | <b>1</b>     |
| 1.1 The exposure side of the equation                            | 1            |
| 1.1.1 Surveys and monitoring programmes                          | 2            |
| 1.1.2 Wildlife health considerations                             | 3            |
| 1.1.3 Human health considerations                                | 4            |
| 1.1.4 Environmental quality                                      | 6            |
| 1.1.5 Design of monitoring programmes                            | 8            |
| 1.2 The toxicity side of the equation                            | 11           |
| 1.2.1 Broad studies of lethal levels                             | 11           |
| 1.2.2 Tissue levels associated with mortality or indices of harm | 14           |
| 1.3 Hazard assessment  | 16           |
| <br>   |              |
| <b>2 Biomarkers of the nervous system</b>                        | <b>19</b>    |
| 2.1 Esterase inhibition  | 19           |
| 2.1.1 Classification of esterases                                | 19           |
| 2.1.2 Mode of action   | 20           |
| 2.1.3 Factors affecting activity                                 | 21           |
| 2.1.4 Direct mortality caused by cholinesterase inhibitors       | 25           |
| 2.1.5 Summary of experimental studies                            | 27           |
| 2.1.6 Relationship to other biomarkers                           | 32           |
| 2.1.7 Use of esterases as biomarkers                             | 32           |
| 2.2 Biogenic amines  | 37           |
| 2.2.1 Introduction   | 37           |
| 2.2.2 Summary of experimental studies                            | 38           |
| 2.2.3 Factors influencing activity                               | 43           |
| 2.2.4 Relationship to other biomarkers                           | 44           |
| 2.2.5 Use of biogenic amines as a biomarker                      | 45           |

|          |  |           |
|----------|--|-----------|
| <b>3</b> | <b>Biomarkers of the reproductive system</b>                   | <b>46</b> |
| 3.1      | Studies of the breeding cycle                                  | 48        |
| 3.1.1    | Introduction   | 48        |
| 3.1.2    | Laboratory experiments   | 50        |
| 3.1.3    | Experimental field studies                                     | 53        |
| 3.1.4    | Observations on untreated individuals                          | 54        |
| 3.2      | Studies on embryos   | 56        |
| 3.3      | Hormones   | 58        |
| 3.3.1    | Effects of polyhalogenated aromatic hydrocarbons               | 59        |
| 3.3.2    | Effects of organophosphates                                    | 64        |
| 3.3.3    | Effects of oil   | 65        |
| 3.3.4    | Receptors  | 65        |
| 3.3.5    | Summary  | 68        |
| <b>4</b> | <b>Studies on genetic material</b>                             | <b>70</b> |
| 4.1      | Introduction   | 70        |
| 4.2      | RNA/DNA ratio  | 71        |
| 4.3      | DNA adducts  | 72        |
| 4.4      | DNA strand breakage  | 75        |
| 4.5      | Degree of methylation of DNA                                   | 78        |
| 4.6      | Sister chromatid exchange                                      | 79        |
| 4.7      | Use of genetic material in monitoring                          | 82        |
| <b>5</b> | <b>Mixed function oxidases</b>                                 | <b>86</b> |
| 5.1      | Introduction   | 86        |
| 5.2      | Nomenclature   | 87        |
| 5.3      | General description of the system                              | 87        |
| 5.4      | Factors influencing activity                                   | 89        |
| 5.5      | Interactions with other biomarkers                             | 95        |
| 5.6      | Mechanism of action, receptors and dioxin equivalents          | 96        |
| 5.7      | Use of mixed function oxidases as biomarkers                   | 101       |
| <b>6</b> | <b>Thyroid function, retinols, haem and regulatory enzymes</b> |           |
| 6.1      | Thyroid function   | 108       |
| 6.1.1    | Introduction   | 108       |
| 6.1.2    | Summary of experimental data                                   | 108       |
| 6.1.3    | Factors influencing activity                                   | 113       |
| 6.1.4    | Interactions with (or relationship to) other biomarkers        | 113       |
| 6.1.5    | Use of thyroid function as a biomarker                         | 114       |
| 6.2      | Vitamin A (retinoids)  | 117       |
| 6.2.1    | Introduction   | 117       |
| 6.2.2    | Summary of experimental data                                   | 118       |
| 6.2.3    | Factors influencing activity                                   | 120       |
| 6.2.4    | Interactions with other biomarkers                             | 121       |

|          |   |            |
|----------|---|------------|
| 6.2.5    | Use of retinoids as biomarkers  | 123        |
| 6.3      | Haem, porphyrins and inhibition of aminolevulinic acid dehydratase (ALAD) by lead | 125        |
| 6.3.1    | Porphyrins: an introduction   | 125        |
| 6.3.2    | Summary of experimental studies   | 127        |
| 6.3.3    | Interrelationship with other biomarkers   | 129        |
| 6.3.4    | Use of porphyrins as biomarkers   | 132        |
| 6.3.5    | Inhibition of ALAD by lead  | 134        |
| 6.3.6    | Factors affecting ALAD activity   | 134        |
| 6.3.7    | Interaction with other biomarkers   | 135        |
| 6.3.8    | Use of ALAD as a biomarker  | 136        |
| 6.4      | Enzyme activity   | 138        |
| 6.4.1    | Introduction  | 138        |
| 6.4.2    | Amino acid metabolism   | 139        |
| 6.4.3    | Carbohydrate metabolism: glycolysis   | 145        |
| 6.4.4    | Oxidative phosphorylation   | 148        |
| 6.4.5    | Phosphatases  | 150        |
| 6.4.6    | Use of enzyme activity as a biomarker   | 151        |
| <b>7</b> | <b>Behavioural effects: their relationship to physiological changes</b>           | <b>155</b> |
| 7.1      | Introduction  | 155        |
| 7.2      | Types of tests used   | 156        |
| 7.3      | Behavioural effects of polyhalogenated aromatic hydrocarbons                      | 157        |
| 7.4      | Behavioural effects of organophosphates   | 157        |
| 7.5      | Behavioural effects of heavy metals and other pollutants                          | 160        |
| 7.6      | Relationship of behavioural effects to biomarkers                                 | 165        |
| <b>8</b> | <b>Environmental immunotoxicology</b>   | <b>167</b> |
| 8.1      | Introduction  | 167        |
| 8.2      | The immune system as a target for xenobiotic interaction                          | 168        |
| 8.2.1    | Immunodeficiency and immunosuppression  | 170        |
| 8.2.2    | Altered host resistance to infections   | 171        |
| 8.2.3    | Hypersensitivity, allergy and pseudoallergy                                       | 172        |
| 8.2.4    | Autoimmunity  | 173        |
| 8.2.5    | Immunopotentialiation   | 174        |
| 8.3      | Relationship of immunotoxicology and other toxic effects                          | 174        |
| 8.3.1    | Immunotoxicity and hepatotoxicity   | 174        |
| 8.3.2    | Immunotoxicity and nephrotoxicity   | 175        |
| 8.3.3    | Immunotoxicity and neurotoxicity  | 175        |

|                   |   |            |
|-------------------|---|------------|
| 8.3.4             | Immunotoxicity and impairment of metabolism/<br>detoxification            | 176        |
| 8.3.5             | Immunosuppression and mutagenicity/carcinogenicity                        | 177        |
| 8.4               | Immunotoxic chemicals   | 177        |
| 8.4.1             | Immunotoxicology of heavy metals, organometals and<br>metalloids          | 177        |
| 8.4.2             | Immunotoxicology of aromatic hydrocarbons                                 | 179        |
| 8.4.3             | Immunotoxicology of halogenated hydrocarbons                              | 180        |
| 8.4.4             | Immunotoxicology of carbamates and<br>organophosphates                    | 183        |
| 8.5               | Assessment and prediction of immunotoxicity                               | 184        |
| 8.6               | Application of immunoassays in environmental studies                      | 187        |
| 8.7               | Conclusions   | 188        |
| <b>9</b>          | <b>The use of animals in wildlife toxicology</b>                          | <b>190</b> |
| 9.1               | Introduction  | 190        |
| 9.2               | The LD <sub>50</sub> and related tests                                    | 191        |
| 9.3               | Comparison of measurements in blood to organs                             | 193        |
| 9.4               | The role of tissue culture experiments                                    | 197        |
| 9.5               | Statistical considerations  | 200        |
| <b>10</b>         | <b>The role of biomarkers in environmental assessment</b>                 | <b>201</b> |
| 10.1              | Biomarkers and the epidemiological approach                               | 201        |
| 10.2              | Current status of monitoring based on biomarkers                          | 204        |
| 10.3              | Relationship between chemical exposure and<br>biomarker response          | 205        |
| 10.3.1            | Availability of biomarkers that respond to major<br>classes of pollutants | 205        |
| 10.3.2            | Sensitivity of response of biomarkers                                     | 206        |
| 10.4              | Relationship between responses of biomarkers to<br>adverse effects        | 211        |
| 10.4.1            | Extrapolation to harm at the individual level                             | 212        |
| 10.4.2            | Extrapolation to harm at the population and<br>community level            | 220        |
| 10.5              | Strategy for using biomarkers   | 222        |
| <b>Appendix 1</b> | Latin names of species referred to in text                                | <b>227</b> |
| <b>Appendix 2</b> | Abbreviations   | <b>231</b> |
| <b>References</b> |   | <b>236</b> |
| <b>Index</b>      |   | <b>282</b> |